Clinical trial · no report yet · Phase 2
STIMULUS-MDS1
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
- NCT03946670 ↗
- Terminated
- Novartis Pharmaceuticals
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 11 | |
| YouTube | 3 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Myelodysplastic Syndromes
- Interventions
- MBG453; Placebo; Hypomethylating agents
- Arms
- MBG453 + hypomethylating agents · Experimental
- Placebo + hypomethylating agents · Placebo comparator
- Enrollment
- 127
- Primary outcomes
- Complete Remission (CR) Rate
- Progression Free Survival (PFS)
- Sponsor
- Novartis Pharmaceuticals
- Start
- Jun 4, 2019
- Primary completion
- Apr 26, 2022
- Results posted
- Yes
- Registry record
- NCT03946670 · updated Jan 13, 2026
Publications
linked from the registry- Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5. PubMed 38065203